Piperacillin induced bone marrow suppression: a case report
Tóm tắt
Piperacillin (and piperacillin/tazobactam) is a commonly prescribed antibiotic and is generally considered safe. We report a case of piperacillin induced bone marrow suppression. A 19-year-old boy was being treated with piperacillin followed by piperacillin/tazobactam for infected pancreatic pseudocyst. After 21 days of treatment, he developed neutropenia and thrombocytopenia. These reversed promptly after stopping piperacillin/tazobactam. The time course of events suggested that piperacillin was the cause of bone marrow suppression in this patient. Bone marrow suppression is a serious adverse effect of piperacillin, which should be kept in mind while treating patients with this drug.
Tài liệu tham khảo
Kaucers A, Crowe SM, Grayson ML, Hoy JF, ed: The use of antibiotics: A clinical review of antibacterial, antifungal and antiviral drugs. Oxford: Butterworth Heinemann. 1997, 5
Winston DJ, Murphy W, Young LS, Hewitt WL: Piperacillin therapy for serious bacterial infections. Am J Med. 1980, 69: 255-261.
Lutz B, Mogabgab W, Holmes B, Pollock B, Beville R: Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin. Antimicrob Agents Chemother. 1982, 22: 10-14.
Bressler RB, Huston DP: Piperacillin-induced anemia and leukopenia. South Med J. 1986, 79: 255-256.
Kirkwood CF, Lasezkay GM: Neutropenia associated with mezlocillin and piperacillin. Drug Intell Clin Pharm. 1985, 19: 112-114.
Sugimoto M, Wakabayashi Y, Shiokawa Y: A case of piperacillin induced leucopenia whose CFU-C derived colony was inhibited in vitro by the coexisting addition of drug, serum, and mononuclear cells. Rinsho Ketsueki. 1984, 25: 197-202.
Wilson C, Greenhood G, Remington JS, Vosti KL: Neutropenia after consecutive treatment courses with nafcillin and piperacillin. Lancet. 1979, 1: 1150-10.1016/S0140-6736(79)91834-8.
Reichardt P, Handrick W, Linke A, Schille R, Kiess W: Leukocytopenia, thrombocytopenia and fever related to piperacillin/tazobactam treatment – a retrospective analysis in 38 children with cystic fibrosis. Infection. 1999, 27: 355-356. 10.1007/s150100050042.
Ruiz-Irastorza G, Barreiro G, Aguirre C: Reversible bone marrow depression by high-dose piperacillin/tazobactam. Br J Haematol. 1996, 95: 611-612. 10.1046/j.1365-2141.1996.d01-1952.x.
Gerber L, Wing EJ: Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin Infec Dis. 1995, 21: 1047-1048.
Neftel KA, Hauser SP, Müller MR: Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985, 152: 90-98.
Singh N, Yu VL, Mieles LA, Wagener MM: Beta-lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med. 1993, 94: 251-256.
Thickett KM, Wildman MJ, Fegan CD, Stableforth DE: Haemolytic anaemia following treatment with piperacillin in a patient with cystic fibrosis. J Antimicrob Chemother. 1999, 43: 435-436. 10.1093/jac/43.3.435.
Olivera E, Lakhani P, Watanakunakorn C: Isolated severe thrombocytopenia and bleeding caused by piperacillin. Scand J Infect Dis. 1992, 24: 815-817.
Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ: Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis. 1987, 155: 1242-1248.
Moore M, McNamara TR, Johnson J: Elevated bleeding time and epistaxis associated with piperacillin therapy. South Med J. 1985, 78: 363-
Yata Y, Miyagiwa M, Inatsuchi S, Hiraiwa Y, Murakami J, Kato T, Takahara T, Watanabe A: Thrombotic thrombocytopenia purpura caused by piperacillin successfully treated with plasma infusion. Ann Hematol. 2000, 79: 593-595. 10.1007/s002770000195.
Perez-Vazquez A, Pastor JM, Riancho JA: Immune thrombocytopenia caused by piperacillin/tazobactam. Clin Infect Dis. 1998, 27: 650-651.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6904/3/2/prepub